Raw data, analytical data, and graphs for upcoming papers titled “ Is penicillin still the best choice for erysipelas? A retrospective study based on survival analysis. ”|抗生素治疗数据集|生存分析数据集

<strong>Abstract</strong> <em><strong>Objectives:</strong></em> Although penicillin has historically been the first line of defence against all skin infections, there is disagreement over the best antibiotic regimen for cellulitis and erysipelas. Our goal was to determine the best empiric antibiotic dosage for individuals with lower extremity erysipelas. <em><strong>Methods:</strong></em> In Changzhou Wujin People's Hospital, patients who were diagnosed with lower extremity erysipelas between January 2016 and May 2023 were the subject of retrospective research. Through Cox regression analysis, clinical characteristics such as age, gender, underlying disorders, the types of antibiotics taken following a diagnosis, hospital stay duration, and disease outcomes were gathered and evaluated. Patients who received intravenous antibiotic treatment for ten days or fewer were classified as cured or endpoint events, whereas those who received the treatment for more than ten days were classified as uncured or censoring. Patients were considered lost to follow-up if their antibiotic regimen changed within 10 days. For underlying illnesses, types of antibiotic usage, and cure distributions, Kaplan-Meier survival curves were constructed. Log-rank tests were then used to compare the distributions. <em><strong>Results:</strong></em> We included 281 episodes of erysipelas (237 cured, 44 uncured). The effectiveness of four distinct antibiotic kinds was assessed using Kaplan-Meier survival curves. Second-generation cephalosporins had the shortest median time to cure out of the bunch (4 days). A univariate study utilising the Cox proportional hazards regression model found that diabetes (P = 0.02&lt;0.05), hypertension (P = 0.00&lt;0.05), and kinds of antibiotics (P = 0.00&lt;0.05) were all significantly associated with the prognosis of patients with erysipelas of the lower extremities. Then, by incorporating each of them in the multivariate analysis, the AHR was collected. <em><strong>Conclusions:</strong></em> Patients with erysipelas of the lower extremities tended to respond best to second-generation cephalosporins as an empiric treatment option. More time would be spent in the hospital for patients with diabetes or hypertension than for those without these underlying conditions.